Gilead Sciences (GILD) Tops Q4 EPS by 1c, Offers Guidance
Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.86, $0.01 better than the analyst estimate of $1.85. Revenue for the quarter came in at $7.93 billion versus the consensus estimate of $7.68 billion.
GUIDANCE:
Gilead Sciences sees FY2026 EPS of $8.45-$8.85, versus the consensus of $8.76.
For the full year 2026, Gilead expects:
(in millions, except per share amounts) |
| February 10, 2026 Guidance | |||||
| Low End | High End | |||||
Product sales |
| $ | 29,600 |
| $ | 30,000 | |
Product sales excluding Veklury |
| $ | 29,000 |
| $ | 29,400 | |
Veklury |
| $ | 600 |
| $ | 600 | |
Diluted EPS |
| $ | 6.75 |
| $ | 7.15 | |
Non-GAAP diluted EPS |
| $ | 8.45 |
| $ | 8.85 | |
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.